The clinicopathologic features of 32 @entity189 with @entity705 are reported. Each @entity5 consisted of invasive @entity420 accompanied by a cartilaginous or osseous component. In 10 @entity5 , this consisted of cartilage and in 2 the heterologous element was osteoid or bone exclusively. The remaining 20 @entity5 contained a mixture of cartilaginous and osseous components. All @entity1 were @entity1 ; mean age was 56 years. Twenty-four @entity1 were treated using mastectomy and eight by local excision. Twenty-six @entity1 underwent axillary lymph node dissection. Lymph node @entity3 were detected in 6 of the 26 (23%) @entity1 who underwent axillary dissection. Clinical follow-up was available for 29 of 32 @entity1 (91%). Local recurrence or distant @entity3 developed in 6 @entity1 (21%) within 2 years of initial treatment, and 4 of these @entity1 died of @entity189 . The overall 5-year survival rate was 60%. When compared with control @entity1 with infiltrating @entity189 , the group with @entity189 tended to have a more favorable prognosis after adjustment for nodal status and @entity5 size. The prognosis of @entity1 with metaplastic @entity189 with @entity705 is dependent on @entity5 stage at diagnosis. Immunohistochemical studies for 34BE12, @entity876 , @entity995 protein, @entity1722 (polyclonal), @entity470 , and @entity4910 were performed in 18 cases. Positive immunohistochemical staining was found as follows: 34BE12: n = 13 (72%); @entity876 : n = 11 (61%); @entity995 protein: n = 12 (66%); @entity1722 /neu: n = 2 (11%); @entity470 : n = 7 (38%); and @entity1364 Dm: n = 5 (28%). Positive staining for 34BE12 was observed in the @entity3909 component in 5 (38%) of the @entity5 , in the metaplastic component in 2 (15%), and in both elements in 6 (64%). A @entity876 staining was observed in the @entity2483 (36%) of 11 @entity876 -positive @entity5 . No disparity in @entity876 staining was noted between the epithelial and metaplastic elements in the other @entity876 -positive @entity5 . Expression of these markers did not correlate with clinicopathologic features such as @entity1 age, @entity5 size, @entity5 type, relative proportion of metaplastic elements, and axillary nodal status and was not predictive of disease-free survival.

XXXX of the breast with osteocartilaginous heterologous elements.

@entity1 :: ('9606', 'Species') :: ['patient', 'women', 'patients'] @entity1364 :: ('5111', 'Gene') :: ['cyclin'] @entity705 :: ('MESH:D015831', 'Disease') :: ['heterologous osteocartilaginous elements'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'tumor', 'neoplasm', 'tumors'] @entity470 :: ('1956', 'Gene') :: ['epidermal growth factor receptor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['metaplastic carcinomas', 'metaplastic carcinoma', 'duct carcinoma', 'metastatic carcinoma', 'mammary carcinoma'] @entity4910 :: ('595', 'Gene') :: ['cyclin D1'] @entity3909 :: ('MESH:D055756', 'Disease') :: ['carcinomatous'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity2483 :: ('MESH:C566443', 'Disease') :: ['carcinomatous component exclusively in 4'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1722 :: ('2064', 'Gene') :: ['HER/2neu', 'HER2'] @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma']
@entity189 :: (MESH:D002277,Disease) :: ['Metaplastic carcinoma']
